These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24277416)

  • 1. Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.
    Tsirakis G; Roussou P; Pappa CA; Kolovou A; Vasilokonstantaki C; Miminas I; Kyriakaki S; Alegakis A; Alexandrakis MG
    Med Oncol; 2014 Jan; 31(1):778. PubMed ID: 24277416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
    Terpos E; Politou M; Viniou N; Rahemtulla A
    Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.
    Terpos E; Politou M; Szydlo R; Goldman JM; Apperley JF; Rahemtulla A
    Br J Haematol; 2003 Oct; 123(1):106-9. PubMed ID: 14510950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.
    Abe M; Hiura K; Wilde J; Moriyama K; Hashimoto T; Ozaki S; Wakatsuki S; Kosaka M; Kido S; Inoue D; Matsumoto T
    Blood; 2002 Sep; 100(6):2195-202. PubMed ID: 12200385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients.
    Tsirakis G; Pappa CA; Kaparou M; Katsomitrou V; Hatzivasili A; Alegakis T; Xekalou A; Stathopoulos EN; Alexandrakis MG
    Eur J Histochem; 2011; 55(3):e21. PubMed ID: 22073368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
    Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
    Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.
    Oyajobi BO; Franchin G; Williams PJ; Pulkrabek D; Gupta A; Munoz S; Grubbs B; Zhao M; Chen D; Sherry B; Mundy GR
    Blood; 2003 Jul; 102(1):311-9. PubMed ID: 12649140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of CCL3 protein (monocyte inflammatory protein-1 alpha) in lymphoid malignancy.
    Hamed H; Zaki S
    Egypt J Immunol; 2007; 14(1):63-72. PubMed ID: 18689282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
    Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
    Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
    Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
    Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma bone disease.
    Sezer O
    Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIP-1 alpha and myeloma bone disease.
    Roodman GD; Choi SJ
    Cancer Treat Res; 2004; 118():83-100. PubMed ID: 15043189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.
    Pappa CA; Tsirakis G; Psarakis FE; Kolovou A; Tsigaridaki M; Stafylaki D; Sfiridaki K; Alexandrakis MG
    Med Oncol; 2013 Mar; 30(1):363. PubMed ID: 23266941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
    Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
    Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.